T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 Registration Statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment pertains to a proposed public offering of securities, including up to 3,322,259 shares of common stock, Pre-Funded Warrants to purchase an equivalent number of shares, and Series B-1 and B-2 Common Warrants to purchase up to 3,322,259 shares of common stock each. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities or proceeds required for closing. The securities may be sold to purchasers whose ownership would exceed 4.99% of outstanding common stock, in the form of Pre-Funded Warrants...Show More

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 Registration Statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment pertains to a proposed public offering of securities, including up to 3,322,259 shares of common stock, Pre-Funded Warrants to purchase an equivalent number of shares, and Series B-1 and B-2 Common Warrants to purchase up to 3,322,259 shares of common stock each. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities or proceeds required for closing. The securities may be sold to purchasers whose ownership would exceed 4.99% of outstanding common stock, in the form of Pre-Funded Warrants, to avoid exceeding the ownership threshold. The offering is expected to close no later than May 15, 2024, with T2 Biosystems' common stock listed on the Nasdaq Capital Market under the symbol 'TTOO.' The closing price of T2 Biosystems' common stock on Nasdaq as of May 1, 2024, was $3.01 per share. The company intends to use the net proceeds for working capital and general corporate purposes, including sales and marketing, manufacturing, and clinical development costs.